In recent years, the incorporation of pembrolizumab, an anti-programmed death 1 (PD-1) monoclonal antibody (mAb), and bevacizumab, a humanized anti-vascular endothelial growth factor (VEGF) mAb, has significantly transformed the therapeutic paradigm for cervical cancer. Here, VEGFA is linked to cervical carcinoma.